Although TGF-β can act as an EMT suppressor in premalignant stages of gliomas (29), the main regulatory mechanism for TGF-β is to promote EMT through the TGF-β/Smad pathway in progression stages (30, 31). This evidence concerns the gene TGFB1 and central nervous system cancer.